Plosbrio and Poviztra in Canada: Novo Nordisk’s Lower-Price Semaglutide, Explained
On December 22, 2025, Health Canada approved two new semaglutide products from Novo Nordisk: Plosbrio and Poviztra. These are not generics. They are the same formulations as Ozempic and Wegovy, respectively — same active ingredient, same manufacturer — sold under new brand names at what Novo Nordisk says will be lower prices.
This page covers the factual details: what these products are, how they compare to existing semaglutide brands, when they may reach pharmacy shelves, and what they mean for pricing in Canada.
What Are Plosbrio and Poviztra?
Both products are manufactured by Novo Nordisk Canada and contain the same active ingredient — semaglutide — as the company’s existing products:
| New Brand | Identical To | Active Ingredient | Manufacturer |
|---|---|---|---|
| Plosbrio | Ozempic | Semaglutide (injection) | Novo Nordisk Canada |
| Poviztra | Wegovy | Semaglutide (injection) | Novo Nordisk Canada |
According to Novo Nordisk, the only differences between these new brands and their existing counterparts are the product names and packaging. The formulation — the drug itself — is unchanged. A Health Canada spokesperson confirmed that Plosbrio and Poviztra “are not generic semaglutide products and have no connection to Health Canada’s review of the generic semaglutide submissions.”
Health Canada Approval
Health Canada approved Plosbrio and Poviztra on December 22, 2025. This approval means the products have met all regulatory requirements and can be legally sold in Canada. However, regulatory approval does not mean the products are immediately available at pharmacies — manufacturer launch timing, distribution logistics, and pharmacy stocking decisions all factor in.
As of February 2026, Novo Nordisk has stated it is “considering” introducing these products to the market. No specific launch date has been publicly announced.
Why New Brand Names? The Pricing Strategy
Canada’s drug pricing framework makes it difficult for a brand-name manufacturer to simply lower the price of an existing product. Price reductions on products listed in provincial formularies can trigger complex regulatory and reimbursement consequences.
By registering new brand names for the same formulation, Novo Nordisk can set a separate, lower price point for Plosbrio and Poviztra without reducing the listed price of Ozempic or Wegovy. Pharmaceutical policy researchers have described this as a strategy that lets the company “bypass” the existing pricing structure and compete directly with generic manufacturers on price.
In practice, this means Novo Nordisk could sell four semaglutide products in Canada simultaneously:
- Ozempic — current brand-name product, current pricing
- Plosbrio — identical formulation, expected lower price
- Wegovy — current brand-name product, current pricing
- Poviztra — identical formulation, expected lower price
Plosbrio vs. Ozempic: Price Comparison
No specific pharmacy prices for Plosbrio have been publicly announced as of February 2026. However, the product’s stated purpose is to compete with generic semaglutide pricing. Here is what we know about the pricing landscape:
| Product | Estimated Monthly Cost (CAD) | Status |
|---|---|---|
| Ozempic (branded) | $220–$265 | Available now at Canadian pharmacies |
| Plosbrio (Novo Nordisk) | TBD — expected lower than Ozempic | Approved; not yet launched |
| Generic semaglutide | ~$60–$100 (estimated) | Pending Health Canada approval; expected Q3 2026 |
Ozempic prices are based on verified Canadian pharmacy data. Plosbrio and generic pricing are not yet confirmed. GLP1Prices.ca will publish verified pharmacy prices for all semaglutide products as they become available.
For current verified pharmacy pricing on Ozempic, see our Ozempic price comparison page.
The Generic Semaglutide Landscape
Plosbrio and Poviztra exist in the context of an approaching generic semaglutide market. Key facts:
- Novo Nordisk’s data exclusivity on semaglutide expired on January 4, 2026, making Canada one of the first Western markets where generic submissions could advance.
- Nine generic semaglutide submissions from five companies are currently under review at Health Canada.
- Generic approvals are expected in Q3 2026, though Health Canada does not pre-announce approval timelines.
- Health Canada has noted that generic approval may take additional time because Novo Nordisk’s semaglutide is produced through biological processes, while some generic versions use chemical synthesis — a distinction that can affect the regulatory review path.
For a detailed breakdown of the generic timeline, see our post on Generic Semaglutide in Canada: 2026 Timeline and Expected Prices.
How This Affects Canadian Semaglutide Pricing
The introduction of Plosbrio and Poviztra adds a new pricing tier to the Canadian semaglutide market. Once these products launch and generic competitors receive approval, the market could include:
- Premium tier: Ozempic and Wegovy at current brand-name prices
- Mid tier: Plosbrio and Poviztra at reduced (but not yet disclosed) prices
- Generic tier: Third-party generic semaglutide at the lowest expected prices
More competition in a market typically pushes prices downward. With Novo Nordisk itself introducing lower-priced alternatives alongside multiple generic entrants, Canadians purchasing semaglutide out-of-pocket may see substantially more pricing options by late 2026.
What GLP1Prices.ca Will Track
When Plosbrio and Poviztra reach pharmacy shelves, GLP1Prices.ca will track their prices using the same method we use for all products: confirmed pricing from specific Canadian pharmacies, verified on a specific date. We do not publish estimated or suggested prices as pharmacy prices.
You will be able to compare Plosbrio pricing against Ozempic, Poviztra against Wegovy, and all semaglutide products against upcoming generics — filtered by province and sorted by price.
To be notified when Plosbrio, Poviztra, or generic semaglutide prices are listed, sign up for our price alert. We send one email when prices go live — no ongoing marketing.
Key Dates to Watch
| Date | Event |
|---|---|
| Dec 22, 2025 | Health Canada approves Plosbrio and Poviztra |
| Jan 4, 2026 | Novo Nordisk’s semaglutide data exclusivity expires |
| TBD (2026) | Plosbrio / Poviztra expected pharmacy launch |
| Q3 2026 (est.) | First generic semaglutide approvals expected |
Frequently Asked Questions
Is Plosbrio the same as Ozempic?
Yes. Plosbrio contains the same semaglutide formulation as Ozempic, manufactured by the same company (Novo Nordisk). The only differences are the brand name and packaging.
Is Poviztra the same as Wegovy?
Yes. Poviztra contains the same semaglutide formulation as Wegovy, manufactured by Novo Nordisk. The brand name and packaging are the only differences.
Are Plosbrio and Poviztra generics?
No. They are branded products from Novo Nordisk — the same company that makes Ozempic and Wegovy. Health Canada has explicitly stated these are not generic products and have no connection to the generic semaglutide submissions under review.
How much will Plosbrio cost?
Novo Nordisk has not publicly disclosed pricing for Plosbrio. The company has indicated the price will be lower than Ozempic, positioned to compete with generic semaglutide. GLP1Prices.ca will publish verified pharmacy prices as soon as the product is available.
When will Plosbrio be available at pharmacies?
Plosbrio received Health Canada approval on December 22, 2025. As of February 2026, Novo Nordisk has not announced a specific pharmacy launch date. The company has stated it is “considering” market introduction.
Will my insurance cover Plosbrio or Poviztra?
Insurance coverage depends on your specific plan and your province’s formulary decisions. Since these are new product registrations, insurers and provincial drug plans will need to make individual listing decisions. Check with your insurance provider for coverage details.
Get notified when generic prices go live
We’ll send one email the moment generic semaglutide prices are listed at Canadian pharmacies. No spam.
Get notified when generic semaglutide becomes available in Canada
Expected Q3 2026 — be the first to know